Laboratory of Chemistry, Department of Applied Sciences, Rajkiya Engineering College (Affiliated to Dr. A.P.J. Abdul Kalam Technical University, Lucknow), Churk, Sonbhadra-231206, India.
Curr Top Med Chem. 2021;21(8):737-752. doi: 10.2174/1568026621666210303145759.
Undoubtedly, antibiotics have saved billions of lives, but lack of novel antibiotics, development of resistance mechanisms in almost all clinical isolates of bacteria, and recurrent infections caused by persistent bacteria hamper the successful treatment of the infections. Due to the widespread emergence of resistance, even the new families of anti-microbial agents have a short life expectancy. Drugs acting on a single target often lead to drug resistance and are associated with various side effects. For overcoming this problem, either multidrug therapy, or a single drug acting on multiple targets may be used. The latter is called 'hybrid molecules,' which are formed by clubbing two biologically active pharmacophores together, with or without an appropriate linker. In this rapidly evolving era, the development of natural product-based hybrid molecules may be a super-alternative to multidrug therapy, for combating drug resistance caused by various bacterial and fungal strains. Coumarins (benzopyran-2-one) are one of the earliest reported plant secondary metabolites having a clinically proven diverse range of pharmacological properties. On the other hand, 1,2,3-triazole is a common pharmacophore in many drugs responsible for polar interactions, improving the solubility and binding affinity to biomolecular targets. In this review, we discuss recent advances in Coumarin-1,2,3-triazole hybrids as potential anti-bacterial agents, aiming to provide a useful platform for the exploration of new leads with a broader spectrum, more effectiveness and less toxicity with multiple modes of action for the development of cost-effective and safer drugs in the future.
毫无疑问,抗生素挽救了数十亿人的生命,但由于新型抗生素的缺乏、几乎所有临床分离菌的耐药机制的发展以及持续存在的细菌引起的反复感染,成功治疗感染的难度加大。由于耐药性的广泛出现,即使是新的抗菌药物家族也只有很短的预期寿命。作用于单一靶点的药物往往会导致耐药性,并伴有各种副作用。为了克服这个问题,可以采用多药治疗或单一药物作用于多个靶点。后者称为“杂合分子”,它是通过将两个具有生物活性的药效团连接在一起形成的,有或没有合适的连接子。在这个快速发展的时代,基于天然产物的杂合分子的开发可能是对抗各种细菌和真菌菌株耐药性的多药治疗的超级替代品。香豆素(苯并吡喃-2-酮)是最早报道的具有临床证明的多种药理学特性的植物次生代谢产物之一。另一方面,1,2,3-三唑是许多药物中的一个常见药效团,负责极性相互作用,提高了与生物分子靶标的溶解度和结合亲和力。在这篇综述中,我们讨论了香豆素-1,2,3-三唑杂合作为潜在的抗菌剂的最新进展,旨在为探索具有更广泛的作用机制、更有效的治疗效果和更小的毒性的新型先导化合物提供一个有用的平台,以开发出更具成本效益和更安全的药物。